Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Hanmi Science Subsidiary Hanmi Pharmaceutical Licenses Fabry Disease Therapy to BioMarin in USD 237.5 Million Deal

By Public Technologies
  • Hanmi Science subsidiary Hanmi Pharmaceutical signed a USD 237.5 million Fabry disease licensing deal with BioMarin on October 29, 2026.
  • The agreement includes USD 35 million upfront, USD 202.5 million in milestone payments, and royalties based on annual net sales.
  • BioMarin receives exclusive worldwide rights to LA-GLA; Hanmi Pharmaceutical and GC retain approval and commercialization rights in South Korea.
  • The long-acting enzyme replacement therapy, also called HM15421, is undergoing Phase 1/2 trials domestically and overseas, with GC jointly developing it.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanmi Science Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030800021), on October 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.